S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Better Than Oil Stocks (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Better Than Oil Stocks (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Better Than Oil Stocks (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Better Than Oil Stocks (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

$0.57
0.00 (0.00%)
(As of 02/22/2024 ET)
Today's Range
$0.56
$0.58
50-Day Range
$0.57
$0.74
52-Week Range
$0.51
$3.28
Volume
19,267 shs
Average Volume
68,922 shs
Market Capitalization
$10.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Trevena MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
868.0% Upside
$5.50 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Trevena in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

761st out of 934 stocks

Pharmaceutical Preparations Industry

347th out of 421 stocks


TRVN stock logo

About Trevena Stock (NASDAQ:TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

TRVN Stock Price History

TRVN Stock News Headlines

Trevena Stock (NASDAQ:TRVN), Short Interest Report
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Trevena Awarded OLINVYK Agreement with Premier, Inc.
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Trevena (NASDAQ: TRVN)
Trevena Shares Rise 18% After Getting $15M Tranche
Biotech Shares Are Running Again!
See More Headlines
Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2023
Today
2/23/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRVN
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$9.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+868.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,670,000.00
Pretax Margin
-949.98%

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$2.25 per share

Miscellaneous

Free Float
16,718,000
Market Cap
$9.82 million
Optionable
Optionable
Beta
1.18
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Ms. Carrie L. BourdowMs. Carrie L. Bourdow (Age 61)
    President, CEO & Chairman
    Comp: $1M
  • Mr. Barry Shin (Age 52)
    Senior VP & CFO
    Comp: $670.02k
  • Dr. Mark A. Demitrack (Age 66)
    Senior VP & Chief Medical Officer
    Comp: $690.32k
  • Dr. Howard A. Rockman M.D.
    Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Joel Solomon
    VP, General Counsel & Chief Compliance Officer
  • Mr. Michael Catalano
    Vice President of Marketing
  • Mr. Robert T. Yoder (Age 58)
    Senior VP, Chief Business Officer & Head of Commercial Operations
    Comp: $490.64k
  • Ms. Patricia M. Drake (Age 58)
    Senior VP & Chief Commercial Officer














TRVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevena stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings
or view top-rated stocks.

What is Trevena's stock price target for 2024?

2 Wall Street analysts have issued 12-month price objectives for Trevena's stock. Their TRVN share price targets range from $2.00 to $9.00. On average, they anticipate the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 868.0% from the stock's current price.
View analysts price targets for TRVN
or view top-rated stocks among Wall Street analysts.

How have TRVN shares performed in 2024?

Trevena's stock was trading at $0.7221 at the beginning of 2024. Since then, TRVN stock has decreased by 21.3% and is now trading at $0.5682.
View the best growth stocks for 2024 here
.

Are investors shorting Trevena?

Trevena saw a increase in short interest in January. As of January 31st, there was short interest totaling 43,800 shares, an increase of 52.6% from the January 15th total of 28,700 shares. Based on an average daily volume of 100,800 shares, the short-interest ratio is currently 0.4 days. Currently, 0.3% of the shares of the stock are short sold.
View Trevena's Short Interest
.

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our TRVN earnings forecast
.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its earnings results on Monday, May, 15th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The biopharmaceutical company earned $0.01 million during the quarter, compared to the consensus estimate of $0.60 million. During the same period last year, the company earned ($2.50) EPS.

When did Trevena's stock split?

Trevena shares reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Trevena own?
Who are Trevena's major shareholders?

Trevena's stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.61%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow.
View institutional ownership trends
.

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVN) was last updated on 2/23/2024 by MarketBeat.com Staff